Antimicrobial peptide

Project ELI

In collaboration with EligoChem, Infex Therapeutics is developing an antimicrobial peptide that specifically targets the bacterial cell membrane over the mammalian counterpart.

These agents target urgent unmet medical need organisms such as E. coli, K. pneumoniae, A. baumannii and P. aeruginosa, for the treatment of serious infections.

The work to date has been conducted by EligoChem and the University of Colorado and has focused on the potential of synthetic peptides — being able to manipulate certain aspects of the synthesis to increase efficacy whilst avoiding potential toxicological and stability issues. The collaboration with the AMR Centre is to expedite the selection and evaluation of a candidate compound for clinical development.

Target product

Novel IV therapeutic for Gram-negative infections

  • Trauma-induced infections, septicaemia, intra-abdominal and urinary tract infections
  • Carbapenem-resistant P. aeruginosa, A. baumannii and Enterobacteriaceae critical unmet medical need


Antimicrobial peptide that specifically disrupts bacterial cell membrane

  • AMPs are found throughout nature and have diverse structures and functions, including antimicrobial activity
  • Low likelihood for resistance and first in class therapeutic
Multidrug-resistant Acinetobacter · U.S. Centers for Disease Control and Prevention - Medical Illustrator
Escherichia coli · National Institute of Allergy and Infectious Diseases (NIAID)